Homeo AI vs NeoHomeo: Practitioner Platform or Review Copilot?

Quick answer

Choose NeoHomeo when the tested job is joining a practitioner or clinic to an early-access platform that advertises patient intake, case management, repertory tools, AI prescription assistance, teleconsultation, doctor discovery, and multi-doctor operations. Choose Homeo AI when the tested job begins with a completed case narrative and requires the practitioner to inspect proposed symptoms, rubric mappings, source passages, remedy differences, corrections, and follow-up changes before accepting an interpretation.

NeoHomeo presents two connected public surfaces. The India practitioner site markets subscriptions and Clinic OS features, while the main NeoHomeo site presents a patient pre-assessment and doctor-matching marketplace. Homeo AI is a narrower case-review copilot. The deciding question is whether a clinic needs a multi-party acquisition and operations platform or a reconstructable practitioner-review path.

This review uses NeoHomeo's live India practitioner page, main product page, and hydrated May 2026 privacy and terms pages as captured on 15 August 2026. They are first-party surfaces controlled by the same brand and linked through canonical metadata and navigation. They document the public offer, but they do not independently validate clinical quality, legal scope, security implementation, plan availability, adoption, uptime, AI accuracy, or outcomes.

What NeoHomeo currently advertises

The India practitioner page describes an early-access product for practitioners, clinics, patients, students, pharmacies, and administrators. For practitioners it advertises AI prescription assistance, case management, repertory access, digital prescriptions, appointments, teleconsultation, and patient records. The clinic tier adds multiple doctors, a clinic dashboard, API access, and custom branding. The patient-facing main site describes AI-assisted pre-assessment followed by matching and handoff to independent homeopathic practitioners.

That range can be genuinely useful if the clinic's bottleneck spans discovery, intake, consultation, and administration. It also means evaluation must cover several user types. A feature visible to a doctor may expose different information to a patient, clinic administrator, pharmacy, or platform operator. Test each role separately and do not infer access boundaries from the marketing diagram.

The India page labels the product as early access. Treat that as a maturity disclosure, not automatically as a reason to reject it. Early access can offer fast learning and direct vendor support, but the clinic needs written expectations for production availability, data migration, backward compatibility, uptime, support, release notices, plan changes, and what happens if a module is withdrawn.

Public practitioner prices and allowances

On 15 August 2026, the India page listed Doctor Basic at INR 999 per month for up to 30 patients and 50 AI assists monthly. Doctor Pro was INR 2,499 per month for up to 150 patients, an advertised unlimited AI-assist allowance, teleconsultation, and broader tools. The Clinic plan was INR 5,999 per month with unlimited patients, multiple doctors, API access, and custom branding.

The word unlimited needs a contract definition. Ask whether it is governed by fair-use limits, rate limits, model costs, queue priority, acceptable-use rules, or a later plan change. For every tier, confirm taxes, annual billing, practitioner and staff seats, patient counting, archived records, AI-assist counting, teleconsult minutes, storage, messages, support, export, renewal, cancellation, refunds, and post-cancellation access.

Also verify whether the price belongs to a live production checkout or an early-access expression of interest. Save the plan page, checkout, order form, and governing terms on the same date. A displayed rupee amount establishes a public offer snapshot, not a permanent entitlement.

The legal-scope gap is a procurement issue

The practitioner page displays Privacy and Terms labels, but during this review they were non-working hash links rather than routes to documents. The connected neohomeo.com application does expose hydrated privacy and terms pages dated May 2026. Its privacy policy covers account, contact, health-history, consultation, and payment information used for pre-assessment, matching, case summaries, service delivery, and operations. It describes Supabase row-level security, encryption claims, assigned-doctor and authorised-operations access, and a process for deletion requests.

The main terms say NeoHomeo connects patients with independent licensed homeopathic practitioners and is not itself the healthcare provider. They require adult use or parental supervision for minors and identify Indian law and Hyderabad jurisdiction. Those provisions are relevant to the patient marketplace.

They do not visibly define the Doctor Basic, Doctor Pro, or Clinic subscription; AI prescription assistance; the Clinic OS; API use; custom branding; staff roles; patient and AI allowances; practitioner exports; clinic ownership of records; or pharmacy and administrator access. That does not prove the subscriptions lack terms. It means the public document scope is not enough for a clinic buyer to map the product shown on the practitioner page.

Before using real information, ask for the exact contracting entity, product schedule, data-processing agreement, practitioner and clinic role definitions, subprocessor list, hosting regions, model providers, training and retention terms, breach notification, record retention, export, deletion, backup removal, support access, and clinical responsibility clauses. Confirm whether the May 2026 marketplace documents apply, are supplemented, or are replaced for the practitioner subscription.

The privacy policy says aggregated or de-identified information may be used for analytics and improving features. Ask how de-identification is performed, whether free text or rare case details can be re-identified, whether clinic opt-out exists, and whether model training is included. Do not treat a marketing phrase such as HIPAA-compliant ready as evidence of a completed assessment or executed agreement.

Where Homeo AI fits

Homeo AI should be evaluated on what happens between the practitioner's original narrative and an accepted analysis. It proposes structure and rubric mappings, keeps transformations available for correction, exposes supporting source material, supports remedy differentiation, and carries reviewed reasoning into follow-up. Its value depends on whether another practitioner can reconstruct and challenge the path.

Homeo AI does not replace NeoHomeo's advertised doctor marketplace, patient portal, teleconsultation, multi-doctor clinic dashboard, API, branded clinic experience, or plan-based patient management. NeoHomeo should not be assumed to reproduce Homeo AI's exact narrative-to-rubric correction trail because it advertises an AI prescription assistant, case management, and repertory access.

If a clinic uses both, define a narrow approved transfer. NeoHomeo may hold patient identity, consent, appointment, marketplace, operational record, and final authorised document. Homeo AI may receive a de-identified completed narrative for review. Move only a practitioner-approved summary back. Do not let a marketplace pre-assessment flow directly into a prescription, and do not let an advertised AI-assist quota become a target for clinical throughput.

A reproducible clinic test

Prepare four completed, de-identified cases: a detailed first consultation, a follow-up with changed modalities, a teleconsultation case with an intentionally ambiguous statement, and a clinic case involving two practitioners. Remove names, phone numbers, dates, addresses, images, payment details, document identifiers, and rare contextual combinations. Use invented patients and appointments.

In NeoHomeo, create separate test roles for a patient, practitioner, second practitioner, and clinic administrator. Follow the patient pre-assessment and doctor-matching path, then test intake, case management, AI assistance, repertory access, prescription drafting, teleconsultation, reassignment, and export. Record which data each role can view, whether an administrator can open narrative or prescription content, whether a patient can distinguish generated material from practitioner-approved advice, and how a correction is represented.

Test the advertised allowances without attempting to exhaust them. Determine what creates a patient count and an AI assist, whether drafts or retries count, whether a deleted or archived patient frees an allowance, and what unlimited means at the Clinic or Pro boundary. Inspect the actual checkout and request the practitioner-specific documents before purchasing. Use no real payment or patient data.

Then test exit. Export the invented account and inspect whether narrative, structured fields, prescriptions, attachments, consent, teleconsult records, role history, and audit history are included. Ask how API-created records are deleted and whether branded clinic pages remain accessible after cancellation.

In Homeo AI, enter the same de-identified narratives. Record which symptoms and rubrics are proposed, accepted, edited, or rejected; which supporting passages are opened; how the ambiguous statement is handled; whether a second practitioner can reconstruct the reasoning; and whether follow-up observations remain distinct from the original case.

Score both products on role isolation, patient communication, correction clarity, source traceability, export completeness, contract coverage, AI data exposure, early-access continuity, actual annual cost, and the time needed to reconstruct a decision. A completed teleconsultation is not evidence that an interpretation is correct. A plausible analysis does not establish that consent, records, or marketplace roles were handled correctly.

Known limits and clinical responsibility

NeoHomeo's prices, plans, role descriptions, security statements, and AI claims are vendor statements. This review did not independently validate its checkout, applications, matching, practitioner licensing, Supabase configuration, encryption, teleconsultation, API, model behavior, data deletion, or clinical outcomes. Its early-access status and the gap between the practitioner offer and publicly reachable legal documents must remain explicit procurement gates.

Homeo AI can also misread a narrative, omit context, map an unsuitable rubric, surface an irrelevant passage, or produce a plausible differential that needs correction. Inspectability supports review; it does not make output correct.

Neither product replaces diagnosis, referral, an emergency-care decision, practitioner judgment, prescription, potency, dosage, or follow-up responsibility. Urgent, severe, or rapidly worsening symptoms require appropriate medical assessment. The practitioner remains responsible for every accepted interpretation, source, record, prescription, and action.

Conditional verdict

Choose NeoHomeo if the clinic needs patient acquisition, pre-assessment, appointments, teleconsultation, multi-doctor operations, and an early-access practitioner platform, and if a role test plus practitioner-specific contract resolves the offer, data, AI, export, and continuity questions. Its multi-party workflow is the real distinction to verify.

Choose Homeo AI if the priority is a focused, reconstructable review from original narrative through practitioner-approved symptoms, rubrics, source inspection, remedy differentiation, and follow-up. If both products are used, establish one authoritative patient record, a de-identified review boundary, and a practitioner-approved one-way handoff before real clinical information enters either workflow.

Official sources checked

• NeoHomeo India practitioner product and pricing page
• NeoHomeo official patient marketplace
• NeoHomeo official May 2026 privacy policy
• NeoHomeo official May 2026 terms

Product facts reviewed 2026-08-15. Confirm current features, prices, source libraries, and terms with the vendor.